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ABSTRACT
The Network of Cancer Genes (NCG) collects
and integrates data on 736 human genes that
are mutated in various types of cancer. For each
gene, NCG provides information on duplicability,
orthology, evolutionary appearance and topological
properties of the encoded protein in a comprehen-
sive version of the human protein-protein interac-
tion network. NCG also stores information on
all primary interactors of cancer proteins, thus
providing a complete overview of 5357 proteins
that constitute direct and indirect determinants of
human cancer. With the constant delivery of
results from the mutational screenings of cancer
genomes, NCG represents a versatile resource for
retrieving detailed information on particular cancer
genes, as well as for identifying common properties
of precompiled lists of cancer genes. NCG is freely
available at: http://bio.ifom-ieo-campus.it/ncg.
INTRODUCTION
Cancer is a genetic disease caused by the accumulation of
deleterious modiﬁcations within the genome of somatic
cells (1). During tumorigenesis, genomic instability leads
to the progressive acquisition of silent (‘passenger’) and
selected (‘driver’) mutations (2). The latter provide
cancer cells with selective growth advantages that initiate
clonal expansion (3). The Cancer Genome Project (CGP)
has the ambitious goal of identifying all genes that are
implicated in the development of cancer (4). The Cancer
Gene Census (CGC) is a part of CGP and collects infor-
mation on more than 370 genes whose mutations are
causally related to cancer (5). Recently, high-throughput
mutational screenings of several cancer types have been
promoted with the aim of identifying mutated genes,
without any hypothesis-driven bias. So far, four of
these high-throughput experiments have been delivered.
Overall, they identiﬁed 380 Candidate Cancer Genes
(CAN-genes) that are mutated in breast, colorectal, pan-
creatic cancers and glioblastoma (6–8). Furthermore, the
pilot experiment from the Tumor Sequencing Project
identiﬁed 26 genes (TSP-genes) mutated in lung
adenocarcinoma (9). Altogether, these studies revealed
that the number of cancer genes is surprisingly high and
they are functionally more heterogeneous than previously
thought. Despite this functional heterogeneity, cancer
genes tend to share ‘systems-level properties’ (10), such
as higher connectivity and lower duplicability when
compared to the rest of human genes (11–13). The
presence of shared properties, which are not strictly
dependent on the gene function, indicates that cancer
genes are fragile components of the human gene
repertoire.
A number of databases have been set up over the years
to collect and organize several types of information related
to cancer, such as somatic mutations of cancer genes (14),
experimental evidence for their involvement in cancer
(15,16) or modiﬁcations in gene expression levels (17,18).
Other databases are specialized on particular types
of cancer (19,20), on single genes (21,22) or on speciﬁc
genomic modiﬁcations (23,24). None of the available
resources, however, focuses on properties of cancer
genes that are not strictly dependent on their function,
but that could help in interpreting cancer as a ‘systems
disease’. Here, we present the Network of Cancer Genes
(NCG, http://bio.ifom-ieo-campus.it/ncg), a database that
stores information on systems-level properties of a com-
prehensive dataset of more than 730 cancer genes. The
collected features are duplicability, evolutionary appear-
ance and topological properties in the human protein–
protein interaction network. Protein interactions have
been successfully used to infer functional links between
proteins (25). In NCG, they are used to understand how
the topological properties of the cancer proteins inside the
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in cancer. NCG can be used to retrieve information on
speciﬁc cancer genes, as well as to identify groups of
cancer genes with identical properties, thus providing a
ﬂexible tool for investigating the complex landscape of
cancer genetic determinants. In this paper, along with a
general description of the features of NCG, we also
provide a speciﬁc example of how NCG can be used by
reporting the properties of PTEN, a tumor suppressor
gene coding for a phosphatidylinositol phosphatase that
is impaired in several cancer types.
MATERIALS AND METHODS
Dataset of human cancer genes
We deﬁne cancer genes as a collection of 736 genes that
are mutated in diﬀerent cancer types and derive from two
diﬀerent data sources. A total of 375 genes come from the
Cancer Gene Census (CGC-genes, December 2008), a
manually curated list of genes with at least two indepen-
dent reports of mutations in primary tumors (5). The
census provides information on the tumor type, as well
as on the genetic eﬀect of the mutation, i.e. whether the
mutation is dominant or recessive (Figure 1A and B).
The remaining 396 genes derive from high-throughput
mutational screenings performed in glioblastoma (7),
breast and colorectal (6), pancreatic (8) cancers (CAN-
genes, Figure 1C) and lung adenocarcinoma (TSP-genes)
(9). CAN- and TSP-genes result from the eﬀort of
massively sequencing the cancer gene repertoire (26),
and provide the ﬁrst unbiased mutational screenings in
diﬀerent cancer types. The lists of literature-curated and
high-throughput derived cancer genes show poor overlap
(Figure 1D), conﬁrming the cancer-speciﬁcity of the
mutational landscape (27). We gather the protein
sequences associated to the 736 cancer genes from the
RefSeq database [March 2009, (28)]. For eight genes no
RefSeq is available and Ensembl protein sequence (29)
is used instead.
Gene duplicability
We deﬁne gene duplicability as in Rambaldi et al. (11). In
brief, we ﬁrst align the protein sequences of all human
genes to the human genome reference assembly (hg18),
using BLAT (30). We then retrieve the best hit of each
gene, deﬁned as the locus on the genome with the
highest score in terms of coverage. By default, all genes
with additional genomic matches that cover at least 60%
of the query length are considered duplicable, while genes
with no additional hits above this threshold are considered
singleton (11). In addition to the results at the default
threshold of 60%, we also provide the possibility of
inspecting additional hits of the same gene covering
higher or lower percentage of the original protein length.
For each duplicated locus, we refer to the genome anno-
tation provided by the UCSC Table Browser (31) to assess
whether it corresponds to a known gene or instead to non-
genic region.
Orthology assignment and evolutionary appearance
We derive the orthology relationships from the eggNOG
database (32). Based on these relationships, we assign the
evolutionary appearance of each cancer gene, deﬁned
as the deepest branch of the tree of life where an
ortholog for that gene can be found. Overall, we divide
the tree of life into seven main branches: Last Common
Ancestor (LCA), which identiﬁes the ancestral cellular
organism, Eukaryotes, Opisthokonts, Metazoans,
Vertebrates, Mammals and Primates. For example, a
human gene whose orthologs are traceable in prokaryotes
is considered to have appeared in the LCA, while a human
gene with orthologs only in fungi and metazoans, but not
in plants, is assumed to be born with Opisthokonts.
Depending on the number of paralogs of a given cancer
gene at each branch, we also derive the corresponding
orthology ratio, deﬁned as the number of co-orthologs
of that human gene in a given lineage. This ratio
provides a useful indication of the number of intra-
lineage duplications that the gene underwent during evo-
lution. Orthology ratio can be 1 to 1 when no duplications
occurred; 1 to N, indicating one-to-many relationship;
N to 1, corresponding to many-to-one relationship; N to
N, when multiple duplications occurred during evolution.
Protein interaction network
In order to gather the most complete representation of
the human protein–protein interaction network, we inte-
grate information from ﬁve resources: the Human Protein
Reference Database (HPRD) (33), BioGRID (34), IntAct
(35), the Molecular INTeraction database (MINT) (36)
Figure 1. Cancer genes collected in NCG. Venn diagrams of the dif-
ferent lists of cancer genes stored in NCG. The Cancer Gene Census
provides information on the cancer type (A) and on the phenotypic
eﬀect of the mutation (B). The CAN-genes reported so far refer to
four cancer types (C). The overlap among the diﬀerent data sources
used in this study is overall very poor (D).
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We only consider primary data on interactions between
human proteins, i.e. putative interactions inferred from
orthology relationships are discarded. The resulting non-
redundant network is composed of 68498 interactions
among 11988 proteins, derived from 19886 independent
literature reports (Table 1). Overall, we ﬁnd 4621 human
proteins that interact with cancer proteins. To provide a
complete view of the network of cancer proteins, NCG
also allows retrieving information on the systems-level
properties for all these primary interactors.
Given the poor overlap between the ﬁve data sets
(Table 1), their integration allows a more complete
coverage of the real interactions for each human protein.
For example, the protein TP53 has a total of 408
interactions in NCG, 237 of which derive from HPRD,
214 from BioGRID, 159 from IntAct, 122 from MINT
and 38 from DIP. The primary interaction network for
each cancer protein is visualized using Medusa (38) and
all interactors are provided with information on their
duplicability, orthology, evolutionary appearance and
possible involvement in cancer.
Database description
NCG is divided into four sections: (i) the gene summary
table, which allows the conversion between diﬀerent gene
and protein identiﬁers, using the Entrez ID as primary
key; (ii) the duplicability table, which includes all results
of the BLAT alignments on the human genome; (iii) the
orthology table, which stores the orthology relationships;
and (iv) the network table, which includes the network
properties for each protein. The data collected in NCG
are stored in a MySQL database. The web interface to
interrogate the database is built in Perl.
RESULTS AND DISCUSSION
Information retrieval
NCG allows retrieving information on cancer genes in
three ways: (i) by using diﬀerent types of identiﬁers,
such as gene symbols, Entrez IDs (39), RefSeq (40) or
Ensembl IDs (29), for speciﬁc genes or groups of genes
of interest; (ii) by selecting precompiled lists of cancer
genes; and (iii) by combining diﬀerent criteria to analyze
genes with similar duplicability, orthology and network
properties. The primary output of the query is a summary
table that provides links to several external databases,
such as Entrez (www.ncbi.nlm.nih.gov/Entrez/), HPRD
(http://www.hprd.org/), OMIM (http://www.ncbi.nlm
.nih.gov/omim/) (41), RefSeq (http://www.ncbi.nlm.nih
.gov/RefSeq/) and Ensembl (http://www.ensembl.org/),
as well as to detailed reports on duplicability, orthology
and network properties.
Duplicability of cancer genes
In accordance with our previous report (11), at 60%
coverage we ﬁnd 104 duplicable cancer genes (14.1% of
the total), which are associated with 336 duplicated loci.
According to the available genome annotation, 44% of
these additional hits correspond to known genes, 15% to
more than one gene and 41% to non-genic regions. Only
22% of duplicable cancer genes duplicate in loci with no
evidence of transcription, indicating that, although our
measure of duplicability is based on direct genome com-
parison, it mostly detects transcribed paralogs.
In the case of the tumor suppressor gene PTEN, we ﬁnd
an almost identical duplicate (97% coverage, 98%
identity) corresponding to PTENP1 (Figure 2A). While
the activity of PTEN as repressor of the AKT pathway
is well documented (42,43), PTENP1 is known to tran-
scribe a processed pseudogene (44,45) but the involvement
in cancer has never been reported. At 10% coverage, an
additional hit is found, which involves the last 50 amino
acids of PTEN and matches to the intronic region between
exons 3 and 4 of ANKFN1 (ankyrin-repeat and ﬁbronectin
type III domain containing 1, Figure 2A).
Orthologs and evolutionary appearance of cancer genes
NCG collects orthology information for 723 out of 736
cancer genes (98.2%), since 13 genes are not present in the
eggNOG database. We ﬁnd that 61% of cancer genes
originated very early in evolution, because orthologs can
be traced back either to LCA or to early Eukaryotes. As
few as 2.5% of cancer genes appeared with Opisthokonts,
17.7% with Metazoans, 15% with Vertebrates and only
the remaining 3.8% with Mammals and Primates. These
results are consistent with previous reports, which assess
that disease genes are overall depleted in recent genes (46).
As expected for an enzyme-coding gene, orthologs of
PTEN are detectable in all branches of the tree of life,
including prokaryotes, where they belong to the inclusive
orthologous group of the tyrosine phosphatases. With the
exception of Danio rerio and Arabidopsis thaliana, whose
genomes underwent whole-genome duplications (47,48),
orthologs of PTEN maintain a strict 1:1 relationship in
all eukaryotic branches (Figure 2B). This suggests an early
diﬀerentiation of PTEN and the maintenance of a strict
singleton status during eukaryote evolution.
Network properties of cancer proteins
For each of the 579 cancer proteins with available network
information (78.7% of the total), we calculate the degree,
Table 1. Integration of protein–protein interaction data
Database Version Proteins Interactions Independent
reports
HPRD (33) 1 September 2007 8697 34938 17770
BioGRID (34) 1 February 2009 7163 23588 8815
IntAct (35) 23 January 2009 7066 22119 1374
MINT (36) 5 February 2009 5151 12653 1210
DIP (37) 26 January 2009 1108 1326 739
NCG 21 June 2009 11988 68498 19886
Data from ﬁve diﬀerent sources are integrated in NCG. To derive a
non-redundant version of the network, proteins are counted as number
of non-redundant Entrez IDs. The number of interactions refers to
non-redundant primary interactions; the independent reports refer to
the number of published papers that deﬁne the interactions.
D672 Nucleic AcidsResearch, 2010, Vol.38,Database issuei.e. the number of interactions, the clustering coeﬃcient,
i.e. the number of interactions between primary
interactors, and the betweenness, i.e. the number of
shortest paths crossing the protein. These parameters
return a measure of connectivity, interconnectivity and
centrality, thus providing a glance of the protein
topology in the network. On the basis of the network
degree, we discriminate between hubs and non-hubs,
where the former are deﬁned as the top 5% most con-
nected proteins in the network. Likewise, we identify the
central nodes of the network, deﬁned as the proteins with
top 5% values of betweenness.
Overall, we ﬁnd 619 human hubs, 78 of which are
cancer proteins (13.4% of the total set). This result is
comparable to previous reports and conﬁrms that cancer
proteins are enriched in hubs when compared to the rest of
human proteins (11,12). We also observe that cancer
proteins have higher betweenness than the rest of human
proteins (P-value <2.2e-16, Wilcoxon test), conﬁrming
that they occupy a central position in the network.
The PTEN has overall 35 interactors, 21 of which are
hubs. This, together with a high betweenness value, makes
PTEN a central node that acts as a bypass between several
hubs inside the human protein–protein interaction
network (Figure 2C). PTEN interacts with TP53
through phosphatase-dependent and -independent
mechanisms (49); it is involved in the phosphorylation of
ADAM29 (50); it attenuates the activity of the tyrosine
kinase receptor PDGFRB (51); and, ﬁnally, it is
phosphorylated by the serine/threonine kinase STK11
(52). This conﬁrms the tendency of cancer proteins to
interact with other cancer proteins, indicating that diﬀer-
ent components of the key biological processes can con-
tribute to tumorigenesis (11).
FUTURE PROSPECTIVE
In the coming years, we will assist to a continuous delivery
of data from the Cancer Genome Project as well as from
other large-scale mutational screenings of cancer genes.
This massive quantity of information will require ad hoc
tools for data organization and mining.
NCG represents a ﬁrst attempt in the direction of a
systematic analysis of cancer genes, and it will be
constantly updated and expanded with the delivery of
new data.
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Figure 2. Duplicability, orthology and network properties of the tumor suppressor gene PTEN.( A) Using the PTEN protein sequence as a query,
three hits are found on the human genome. The best hit corresponds to genomic locus of PTEN, while the two additional hits account for a recent
duplication transcribing for the processed pseudogene PTENP1, and to a short region of identity lying in the intron of ANKFN1, respectively. (B)
The orthology ratio reﬂects the co-orthology relationships of human PTEN at diﬀerent branching points of the tree of life. The only inparalogs of
PTEN in eukaryotes are found in A. thaliana and D. rerio, indicating that this gene maintained a strict singleton status during eukaryotic evolution.
(C) PTEN interacts with 35 other human proteins, four of which are cancer proteins and 22 are hubs. This makes PTEN a central node of the human
protein-protein interaction network.
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